首页> 中文期刊> 《河北医药》 >凉血解毒方药对原发免疫性血小板减少症患者外周血CD4+CD2+5调节性 T 细胞水平的影响

凉血解毒方药对原发免疫性血小板减少症患者外周血CD4+CD2+5调节性 T 细胞水平的影响

         

摘要

目的:观察原发免疫性血小板减少症( ITP)患者治疗前后外周血CD4+CD2+5调节性T细胞水平变化,探讨凉血解毒方药对ITP患者CD4+CD2+5调节性T细胞的作用。方法选取56例ITP患者,男12例,女44例;年龄18~62岁,中位年龄29岁。给以凉血解毒方药治疗(地黄止血胶囊2‘.0 g,3次/d,口服,凉血解毒中草药煎剂升板汤,1剂/d)。患者于治疗前、治疗后90 d分别采取外周静脉血,采用流式细胞术检测CD4+CD2+5调节性T细胞水平。20例健康体检者为正常对照组。结果治疗后第90天,总有效率为73.2%。56例ITP患者治疗前外周血 CD4+CD2+5调节性T细胞表达水平低于正常对照组[(1.01±0.67)%,(2.81±0.52)%],差异有统计学意义( P <0.05);重症ITP患者CD4+CD2+5调节性 T细胞水平低于非重症患者[(0.71±0.23)%,(1.48±0.64)%],差异有统计学意义( P <0.01);患者治疗后90 d CD+4 CD2+5调节性T细胞水平高于治疗前[(1.93±0.53)%,(10.1±0.67)%],与治疗前比较差异有统计学意义( P <0.05);治疗后有效组CD4+CD2+5调节性T细胞水平高于无效组,差异有统计学意义(P <0.05)。结论 ITP 患者外周血CD 4+CD 2+5调节性 T 细胞水平低于正常对照组( P <0.05);凉血解毒方药提升CD4+CD2+5调节性T 细胞水平可能是治疗ITP的疗效机制。%Objective To observe the change of CD 4+CD2+5 regulatory T cells levels in peripheral blood of patients with primary immune thrombocytopenia ( ITP) before and after treatment with Liangxuejiedu prescription ,and to explore the effect of Liangxuejiedu prescription on the levels of CD 4+CD2+5 regulatory T cells in patients with ITP .Methods Fifty-six patients with ITP,including 12 males and 44 females,mean age 29 (age range :18~62yr),were enrolled in the study.The patients were treated with Liangxuejiedu prescription ( Dihuangzhixue capsule 2.0g once,3 times a day per os plus Shwngban decoction,one dose per day).The levels of CD4+CD2+5regulatory T cells in peripheral blood of patients before and 90 days after treatment were detected by flow cytometry .Besides 20 healthy subjects were served as controls .Results After 90-day treatment,the total effective rate was 73.2%.The levels of CD4+CD2+5 regulatory T cells in peripheral blood of patients with ITP were significantly lower than those in control group [(1.01+0.67)%vs (2.81+0.52)%, P <0.05],moreover,the levels of CD4+CD2+5 regulatory T cells in peripheral blood of patients with severe ITP were significantly lower than those of patients with non-severe ITP [(0.71 +0.23)% vs (1.48 +0.64)%, P <0.01].After 90-day treatment,the levels of CD4+CD2+5 regulatory T cells in peripheral blood of patients with ITP were significantly higher than those before treatment [(1.93 +0.53)%vs (1.01+0.67)%, P <0.05],furthermore,the levels of CD4+CD2+5 regulatory T cells in effectiveness group were significantly higher than those in inefficiency group ( P <0.05).Conclusion The levels of CD4+CD2+5 regulatory T cells in peripheral blood of patients with ITP are significantly lower than those in control group ,and the increase of levels of CD 4+CD2+5 regulatory T cells caused by Liangxuejiedu prescription may be the action mechanism in treatment of ITP .

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号